东菱克栓酶治疗不稳定型心绞痛的临床研究  

Clinical studies on treatment with batroxobin for unstable angina pectoris

作　　者：孙树印[1] 张瑞华[1] 焦华[1] 

机构地区：[1]山东省济宁市第一人民医院,山东济宁272111

出　　处：《中国中西医结合急救杂志》2000年第5期300-301,共2页Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care

摘　　要：目的 :探讨东菱克栓酶 (DF 5 2 1)治疗不稳定型心绞痛 (U A)的疗效及安全性 ,为临床应用提供依据。方法 :75例 U A患者于发病后第 1,3,5日分别给予 DF 5 2 13种剂量 :10 BU,5 BU,5 BU,溶于 2 0 0 m l生理盐水中静滴。并选 77例 U A患者用低分子量肝素治疗作对照。结果 :75例患者经用 DF 5 2 1治疗后 ,临床疗效总有效率 84.0 % ,心电图疗效总有效率 6 9.3% ,平均起效时间为用药后 5 6小时 ,复发率 2 1.3% ,3个月后急性心肌梗死 (AMI)发生率 6 .6 % ,血浆纤维蛋白原浓度明显下降 (P<0 .0 1) ,与低分子量肝素组同期比较明显降低 (P<0 .0 5和 P<0 .0 1)。且无明显出血及过敏等不良反应。结论 :DF 5 2 1治疗 U A疗效肯定 。Objective:To evaluate the clinically curative effects outcome and security of batroxobin (DF521) on unstable angina pectoris (UAP) in order to provide the evidance for clinical use.Methods:Seventyfive patients with UAP(treated group) were treated with DF521 in dosage of 10,5 and 5 BU dissolved+ 200 ml normal saline infused intravenously at the first day,the third day and the fifth day respectively.In control group,77 patients with UAP were treated with low molecular weight heparin.Results:After therapy with DF521 in treated group,the improvement rate of clinical symptoms was 84 0%,the effective rate of electrocardiogram was 69 3%,the reaccurrance rate was 21 3%,attack rate of acute myocardial infarction (AMI) within 3 months was 6 6%,the fibrinogen concentration in the blood was decreased significantly compared with low molecular weight heparin treatment group ( P <0 01).The average effective time was 56 hours,and sideeffects such as obvious hemorrhage and allegic reaction were not found.Conclusions:DF521 can be used in treating UAP and is effective,simple and safe.

关 键 词：不稳定型心绞痛 东菱克栓酶 肝素 治疗 

分 类 号：R541.4[医药卫生—心血管疾病]